Century Therapeutics (IPSC) Depreciation & Amortization (CF) (2020 - 2026)

Century Therapeutics (IPSC) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 6.74% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $12.9 million (down 3.11% YoY), while the FY2025 annual figure was $13.1 million, down 1.53% from the prior year.
• Depreciation & Amortization (CF) declined to $3.0 million in Q1 2026 per IPSC's latest filing, from $3.6 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.6 million in Q4 2023 and bottomed at $1.2 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $3.0 million across 5 years, with a median of $3.2 million in 2025.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 170.03% — and 2025, when it dropped 7.54%.
• Century Therapeutics' Depreciation & Amortization (CF) stood at $2.8 million in 2022, then climbed by 25.16% to $3.6 million in 2023, then declined by 6.59% to $3.3 million in 2024, then increased by 6.99% to $3.6 million in 2025, then retreated by 15.38% to $3.0 million in 2026.
• Business Quant data shows IPSC's Depreciation & Amortization (CF) at $3.0 million in Q1 2026, $3.6 million in Q4 2025, and $3.1 million in Q3 2025.